EYLEA(R) (aflibercept) Injection Improves Diabetic Retinopathy and Reduces Vision-Threatening Complications in Phase 3 Trial

First trial in non-proliferative diabetic retinopathy to show both a reduction in vision-threatening complications and in development of diabetic macular edema Both every 8-week and every 16-week dosing groups met primary and key secondary endpoints at ... Biopharmaceuticals, Ophthalmology Regeneron Pharmaceuticals, EYLEA, aflibercept, diabetic retinopathy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news